Pulmonary Embolism (PE)
18
4
6
11
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 18 trials
100.0%
+13.5% vs benchmark
11%
2 trials in Phase 3/4
36%
4 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (18)
Pulmonary Embolism and Right-to-Left Shunts
Repeated Examinations for Typing Pulmonary Embolism
ULTRAsound-assisted Catheter-guided Thrombolysis for Intermediate-high Risk Patients With PE
Effectiveness and Cost-effectiveness of VTE Prevention Strategies in Gynecological Surgery
Repositioning the Bolus Tracking ROI to the Superior Vena Cava in CTPA Facilitates Contrast Volume Reduction
Pulmonary Embolism Following Viper's Bites: A Case Report
Acostream Use in Patients With High Risk and Intermediate-risk Acute Pulmonary Embolism
To Compare and Evaluate the Oral Bioavailability of Edoxaban 60 mg Film Coated Tablet With That of Lixiana® 60 mg Filmtabletten (Film Coated Tablet) (Edoxaban) in Healthy, Adult, Human Subjects Under Fasting Conditions
Ultrasound Assessment of Isolated Distal Deep Vein Thrombosis
VTEval Project - Prospective Cohort Studies to Evaluate and Improve Diagnostics, Management Strategies and Risk Stratification in VTE
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
The Study of How Long Participants Stay in the Hospital After Receiving Apixaban for a Blood Clot in the Lung
Treatment of Venous Thromboembolism (VTE) With Either Rivaroxaban or Current Standard of Care Therapy
Soluble Fibrin for Diagnosing Pulmonary Embolism
Evaluation of Soluble Fibrin in Thrombosis Exclusion
Cancer Venous Thromboembolism (VTE)
Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).
Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)